Evidence of recurrent gene fusions in common epithelial tumors.

[1]  F. Mertens,et al.  Successful treatment of a child with t(15;19)‐positive tumor , 2007, Pediatric blood & cancer.

[2]  I. Panagopoulos,et al.  Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer , 2006 .

[3]  A. Evans,et al.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.

[4]  David E. Misek,et al.  Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation , 2006, Clinical Cancer Research.

[5]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[6]  M. Dictor,et al.  Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy , 2006, BMC Cancer.

[7]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[8]  J. Minna,et al.  Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro , 2005, Journal of Medical Genetics.

[9]  G. Stenman.  Fusion oncogenes and tumor type specificity--insights from salivary gland tumors. , 2005, Seminars in cancer biology.

[10]  L. Manuelidis,et al.  Detection of chromosome aberrations in metaphase and interphase tumor cells by in situ hybridization using chromosome-specific library probes , 1988, Human Genetics.

[11]  C. Antonescu,et al.  Midline carcinoma of children and young adults with NUT rearrangement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Eberhardt,et al.  The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. , 2004, Current drug targets. Immune, endocrine and metabolic disorders.

[13]  B. Johansson,et al.  Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer , 2004, Nature Genetics.

[14]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[15]  J. Harbott,et al.  Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. , 2004, Blood.

[16]  T. Kroll.  Molecular events in follicular thyroid tumors. , 2004, Cancer treatment and research.

[17]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[18]  Toshiyuki Yamada,et al.  Molecular biology of the Ets family of transcription factors. , 2003, Gene.

[19]  J. Fletcher,et al.  BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. , 2003, Cancer research.

[20]  P. Sorensen,et al.  Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.

[21]  Pier Paolo Pandolfi,et al.  The Role of PML in Tumor Suppression , 2002, Cell.

[22]  Y. Nikiforov.  RET/PTC rearrangement in thyroid tumors , 2002, Endocrine pathology.

[23]  P. Sorensen,et al.  The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. , 2001, Cancer research.

[24]  J. Rowley,et al.  Chromosome translocations: dangerous liaisons revisited , 2001, Nature Reviews Cancer.

[25]  O. Monni,et al.  New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. , 2001, Cancer research.

[26]  M. Pierotti.  Chromosomal rearrangements in thyroid carcinomas: a recombination or death dilemma. , 2001, Cancer letters.

[27]  K. Albertine,et al.  Cloning and characterization of the cDNA and gene for human epitheliasin. , 2001, European journal of biochemistry.

[28]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[29]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[30]  R. Hubert,et al.  Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. , 2001, Cancer research.

[31]  F. Mitelman,et al.  Recurrent chromosome aberrations in cancer. , 2000, Mutation research.

[32]  P. Sorensen,et al.  The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells , 2000, Oncogene.

[33]  L. Hood,et al.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.

[34]  Johnson M Liu,et al.  Chromatin remodeling and leukemia: new therapeutic paradigms. , 1999, Blood.

[35]  K. Tanaka,et al.  Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). , 1999, Blood.

[36]  J. Fletcher,et al.  Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. , 1998, The American journal of pathology.

[37]  A. Andrén-sandberg,et al.  Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations , 1998, Genes, chromosomes & cancer.

[38]  T. Hoshino,et al.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Inoue,et al.  Role of the histone deacetylase complex in acute promyelocytic leukaemia , 1998, Nature.

[40]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[41]  M. Pierotti,et al.  Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene , 1998, Oncogene.

[42]  P. Sorensen,et al.  A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.

[43]  H. Rabes,et al.  Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. , 1998, Cancer research.

[44]  L. Mariani,et al.  RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  G. Cimino,et al.  ALL1 gene alterations in acute leukemia: biological and clinical aspects. , 1998, Haematologica.

[46]  M. Pierotti,et al.  Chromosome I rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid‐specific TRK oncogenes , 1997, Genes, chromosomes & cancer.

[47]  A. G. Kessel,et al.  Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Pierotti,et al.  Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. , 1996, Oncogene.

[49]  S Gill,et al.  The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. , 1996, Human molecular genetics.

[50]  D. Ledbetter,et al.  Multicolor Spectral Karyotyping of Human Chromosomes , 1996, Science.

[51]  B. Johansson,et al.  Primary vs. secondary neoplasia‐associated chromosomal abnormalities—balanced rearrangements vs. genomic imbalances? , 1996, Genes, chromosomes & cancer.

[52]  M. Borrello,et al.  The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma , 1996, Molecular and cellular biology.

[53]  D. Ward,et al.  Karyotyping human chromosomes by combinatorial multi-fluor FISH , 1996, Nature Genetics.

[54]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  J. Downing,et al.  Transcriptional regulation by the t(8;21) fusion protein, AML-1/ETO. , 1996, Current topics in microbiology and immunology.

[56]  J. Downing,et al.  MLL fusion genes in the 11q23 acute leukemias. , 1996, Cancer treatment and research.

[57]  J. Zhang,et al.  The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. , 1995, Oncogene.

[58]  A. Lupas,et al.  The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain , 1995, Molecular and cellular biology.

[59]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[60]  J. Rowley,et al.  Detection of Fusion Transcripts Generated by the Inversion 16 Chromosome in Acute Myelogenous Leukemia , 1994 .

[61]  M. Borrello,et al.  A t( 10; 17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma , 1994, Genes, chromosomes & cancer.

[62]  M. Santoro,et al.  Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. , 1994, Oncogene.

[63]  Myriam Alcalay,et al.  The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells , 1993, Cell.

[64]  A. Sandberg,et al.  Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. , 1993, Cancer genetics and cytogenetics.

[65]  J W Gray,et al.  Molecular cytogenetics in human cancer diagnosis , 1992, Cancer.

[66]  M. Santoro,et al.  Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Pierotti,et al.  TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. , 1992, Oncogene.

[68]  P. Freemont,et al.  Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. , 1991, Science.

[69]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[70]  M. Santoro,et al.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.

[71]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[72]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[73]  Rowley Jd.  Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. , 1973 .

[74]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[75]  T. Caspersson,et al.  Differential binding of alkylating fluorochromes in human chromosomes. , 1970, Experimental cell research.

[76]  A M PARFITT,et al.  A.T. 10. , 1964, Lancet.

[77]  P. Nowell,et al.  Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. , 1961, Journal of the National Cancer Institute.

[78]  P. Nowell,et al.  A minute chromosome in human chronic granulocytic leukemia , 1960 .

[79]  P. Jacobs,et al.  Chromosome studies in human leukaemia. , 1959, Lancet.